We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

157 hedge funds and large institutions have $949M invested in Karyopharm Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $7.81M | Put options by funds: $4.85M

1% more funds holding

Funds holding: 155 → 157 (+2)

7% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 27

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

0.45% less ownership

Funds ownership: 6.36% → 5.91% (-0.45%)

28% less capital invested

Capital invested by funds: $1.32B → $949M (-$372M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
157
Holders Change
+2
Holders Change %
+1.29%
% of All Funds
3.17%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
29
Increased
55
Reduced
53
Closed
27
Calls
$7.81M
Puts
$4.85M
Net Calls
+$2.96M
Net Calls Change
-$5.5M

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$17.2M
2
FCM
Frontier Capital Management
Massachusetts
+$14.9M
3
PAI
Palo Alto Investors
California
+$14.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$12.9M
5
BlackRock
BlackRock
New York
+$12.7M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$123M
2
FCM
Farallon Capital Management
California
-$25.3M
3
Goldman Sachs
Goldman Sachs
New York
-$18.5M
4
ACA
Avoro Capital Advisors
New York
-$16.3M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$9.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFS
151
Sowell Financial Services
Arkansas
$2K -$3.67K -15 -65%
S
152
SignatureFD
Georgia
$2K -$1.96K -8 -42%
US Bancorp
153
US Bancorp
Minnesota
$2K – – –
GAM
154
Gemmer Asset Management
California
$2K +$2.2K +9 New
LC
155
Lindbrook Capital
California
$1K -$7.09K -29 -88%
CCMW
156
Cypress Capital Management (Wyoming)
Wyoming
$1K – – –
PFWA
157
Paces Ferry Wealth Advisors
Georgia
$1K +$734 +3 New
CCM
158
Consonance Capital Management
New York
– -$123M -432,787 Closed
FCM
159
Farallon Capital Management
California
– -$25.3M -89,000 Closed
WP
160
Woodline Partners
California
– -$8.77M -30,882 Closed
SFM
161
Sphera Funds Management
Israel
– -$7.44M -26,189 Closed
AI
162
Atom Investors
Texas
– -$7.38M -25,987 Closed
Balyasny Asset Management
163
Balyasny Asset Management
Illinois
– -$4.22M -14,870 Closed
Renaissance Technologies
164
Renaissance Technologies
New York
– -$3.44M -12,120 Closed
PHP
165
Parkman Healthcare Partners
Connecticut
– -$2.29M -8,053 Closed
LCG
166
Lisanti Capital Growth
New York
– -$1.24M -4,371 Closed
TI
167
Trexquant Investment
Connecticut
– -$808K -2,843 Closed
Skandinaviska Enskilda Banken (SEB)
168
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$706K -2,487 Closed
HIM
169
Hillsdale Investment Management
Ontario, Canada
– -$648K -2,280 Closed
Calamos Advisors
170
Calamos Advisors
Illinois
– -$607K -2,136 Closed
Canada Pension Plan Investment Board
171
Canada Pension Plan Investment Board
Ontario, Canada
– -$536K -1,887 Closed
SSA
172
Schonfeld Strategic Advisors
New York
– -$405K -1,423 Closed
CM
173
Caption Management
Oklahoma
– -$379K -1,332 Closed
CL
174
CSS LLC
Illinois
– -$203K -715 Closed
NIT
175
NumerixS Investment Technologies
British Columbia, Canada
– -$103K -364 Closed
4 5 6
7
8

KPTI Hedge Fund Activity: Q3 2020 in Review

157 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2020, worth a combined $949M — down 28% from $1.32B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KPTI positions and 27 closed out — a net gain of 2 holders — while 55 added to existing stakes and 53 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $17.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $123M sold.

  • 157 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2020, up from 155 in Q2 2020.
  • Funds reported $949M of Karyopharm Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
  • 29 funds opened new Karyopharm Therapeutics positions in Q3 2020 and 27 closed out, a net change of +2 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2020 was Two Sigma Investments, an estimated $17.2M added.
  • The largest Karyopharm Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2020.